About US
Contact us
-
The World's Smallest Cooling Circulators with 5.7in Touch ScreenMinistats are the world's smallest cooling circulators. Due to their compact dimensions, the units can be operated in confined spaces such as a laboratory fume cupboard or inside a technical plant.2016/3/28
-
Novartis wraps up China bribery probe with $25M payment to SECNovartis agreed to fork over $25 million to settle aSecurities and Exchange Commissioninvestigation into bribery allegations in China. It's the latest example of corruption claims made against the Swi2016/3/25
-
With Cinqair nod, Teva squares off with GSK in severe asthmaWatch out, GlaxoSmithKline--you've got more competition. Teva ($TEVA) wonFDAapproval Wednesday for its own biologic drug for severe asthma with eosinophilic inflammation, Cinqair. It'll join GSK's ($2016/3/25
-
Helsinn and Eisai extend partnership for prevention of CINVHelsinn and Eisai will continue to co-promote and distribute Aloxi (palonosetron HCl) injection for the prevention of chemotherapy-induced nausea and vomiting (CINV). The move comes as the companies2016/3/24
-
AstraZeneca to acquire rights to Orexo’s OX-CLI programmeAstraZeneca has announced plans to acquire all rights to Orexo´s leukotriene C4 synthase inhibitor programme, OX-CLI project, for $5m. The company partnered with Orexo AB for OX-CLI in 2013 and2016/3/24
-
Bayer's Kovaltry receives FDA approval to treat haemophilia AGerman pharmaceutical company Bayer has received approval from the US Food and Drug Administration (FDA) for Kovaltry Antihemophilic Factor (Recombinant) for the treatment of children and adults with2016/3/23
-
Sanofi, DiCE Molecules to develop oral treatments to replace monoclonal antibodiesFrench drugmaker Sanofi has collaborated with DiCE Molecules to discover potential therapeutics based on unique small molecule discovery platform. The potential new oral treatments would replace mono2016/3/23
-
J&J, BMS are delivering solid sales from new meds. The rest of Big Pharma, not so much: ForbesHow many drugmakers are delivering valuable new meds to the marketplace, saleswise? All too few, says innovation researcher and ex-Big Pharma manager Bernard Munos. In fact, the only two Big Pharmas w2016/3/22
-
Hey, pharma, you're not spending enough on advertising, one expert saysThink pharma spends too much on advertising? Think again, says one expert. Drugmakers need to spread more money into digital channels just to keep up with consumers' growing exposure to ads, says Gayl2016/3/22
-
J&J's Stelara, playing defense in psoriasis, posts more positive Crohn's dataJohnson and Johnson's ($JNJ)Stelarais facing fierce new competition in the psoriasis arena. But the New Jersey drugmaker is looking for ways the med can make its mark in other disease areas, and it's2016/3/21